



Message to Our Future Entrepreneurs

C2I mission is to “Create, Collaborate and Innovate”. Our model is to help bring the next generation of life science companies to market.

C2I has 22,000 sq. ft of total space in Greater Boston area, located just 7 miles from Cambridge and Boston. The accelerator can accommodate biotech, medical device, and instrumentation or digital health companies.

C2I has an additional 1,700sq. ft of biology lab located just 5 minutes from our main facility at 7B Henshaw Street, Woburn.

What we offer

C2I’s unique approach toward supporting early stage companies has provided a valuable foundation for our residents to conduct proof of concept research, refine their vision and jumpstart their businesses.

State of the art Facilities

- ✓ 22,000 sq. ft Fully equipped Chemistry, BL- 2 Biology and Tissue culture labs
- ✓ State of the art instrumentation (In house NMR spectroscopy, analytical and preparative HPLCs, supercritical fluid chromatography (SFC) system, and plate readers, incubators, Biosafety cabinets, centrifuges, inverted electron microscope, and -20/-80 freezers)
- ✓ Generator back up services are being installed
- ✓ Audio/video conference capabilities
- ✓ 24/7 facility access, free parking, & Free Wi-Fi
- ✓ Kitchen and dining and collaboration areas
- ✓ Easy commuter and bus transit access.

Our Services

- ✓ Dedicated in-house CRO services
- ✓ Partner access to vivarium
- ✓ Waste handling and disposal
- ✓ Ordering, Shipping and handling
- ✓ Procurement of capital equipment, chemicals and reagents
- ✓ Mentoring from senior scientists.
- ✓ C2I hosted networking and business development events
- ✓ Ancillary services- Attorneys, Insurance agencies, financial advisors.
- ✓ Access to board of accomplished proven entrepreneurs, executives and advisors
- ✓ C2I is developing active relationships with angel groups, venture capital firms and foundations to aid access to capital for its companies.

Company Spotlight



SQZ Biotechnologies (<http://sqzbiotech.com>): An MIT spinout, SQZ is developing cell-based therapies by modulating cells to provide specific characteristics and functions that fight disease. It has raised \$30M in venture funding and established a \$500M collaboration with Roche.



Kebotix, Inc. (<http://www.kebotix.com>): Kebotix, Inc. is developing an autonomous process for the discovery of novel materials, chemicals, and small molecule pharmaceuticals by linking together automated robotic synthesis and characterization with computational artificial intelligence (AI) methods for materials prediction and synthesis planning. Kebotix has raised a total of \$16.4M in funding over 2 rounds. Their latest funding was raised from a Series A round.



Frequency Therapeutics (<http://www.frequencytx.com>): An MIT spinout, Frequency is advancing progenitor cell activation using targeted drug molecules to regenerate tissue and combat disease. The initial focus is on addressing hearing loss and will extend to other diseases. The company has raised \$33M in venture financing.



LayerBio, Inc. (<http://www.layerbio.com>) LayerBio LLC, one of C2I's flagship companies, is a spinout from an 2013 MIT project aiming to develop *nanoparticle drug delivery systems* to address a variety of therapeutic problems. In 2015 while at C2I, LayerBio was awarded \$200,000 through the Milestone Achievement Program Grant through the Massachusetts Life Sciences Center for manufacturing and product scale-up, along with over \$400,000 in Phase I grants for their projects. Recently, LayerBio received \$1.2M phase II grant from NIH.



SciFluor (<http://www.scifluor.com>): A spinout of Harvard, SciFluor develops proprietary new chemical entities (NCEs) for several therapeutic fields, including ophthalmology, neurology, and fibrosis. The lead drug, SF0166, is currently being studied in patients with Diabetic Macular Edema (DME). The company has raised \$35M in venture financing.

C2I impact on the Biotech Community

Total number of graduating companies since 2013	44
Total number of jobs created	200
Average company stay	12
Ancillary and vendor jobs supported	50
Graduating company success rate	90%
Cumulative economic benefit to biotech ecosystem	636,000,000

The current pipeline of C2I includes new ventures developing RNA sequencing, biomaterials for sustainable water supply, immuno-oncology therapeutics, and antibody and small-molecule therapies for cancer and diabetes treatment, wearable device applications, and precision diagnostics in cancer.

“Fostering the Next generation of Life science Innovation”